Get the Stockscreener App
1,183.46
0.13%
1.57
After Hours:
1183.56
0.10
+0.01%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,183.46, with a volume of 1.91M.
It is up +0.13% in the last 24 hours and down -4.07% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,181.89
Open:
$1185.32
24h Volume:
1.91M
Relative Volume:
0.73
Market Cap:
$1.05T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
42.60
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+2.65%
1M Performance:
-4.07%
6M Performance:
+29.15%
1Y Performance:
+65.61%
1-Day Range:
$1,160.84
$1,190.00
1-Week Range:
$1,134.41
$1,197.79
52-Week Range:
$716.08
$1,292.65
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,183.46 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
271.22 | 652.31B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
264.34 | 468.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
148.78 | 365.09B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
145.46 | 272.89B | 54.66B | 13.58B | 16.05B | 7.0171 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines - Stocktwits
FDA Expands Approval of Eli Lilly's Olumiant for Severe Alopecia Areata in Children (LLY) - GuruFocus
Eli Lilly (LLY) Gains FDA Nod for Olumiant in Pediatric Alopecia Areata - GuruFocus
Lilly's pill is FDA-approved for teens as young as 12 with severe immune-related hair loss - Stock Titan
Eli Lilly stock closes at USD 1,181.89, up 2.68 percent at the closing bell - AD HOC NEWS
Eli Lilly owes Nektar $90 mln in drug collaboration dispute, US jury says - Reuters
Eli Lilly gives a helping hand to Kenosha-area food pantries - Journal Times
Lilly wins approval for once-weekly insulin shot - STAT
Lilly ordered to pay Nektar $90M in damages over rezpeg dispute - FirstWord
Why Is Eli Lilly (NYSE:LLY) Drawing Fresh NYSE Attention? - Kalkine Media
Jury awards Nektar Therapeutics $90M in rezpeg dispute with Eli Lilly - app.dealroom.co
Eli Lilly Did Breach Implied Covenant of Good Faith With Nektar Therapeutics, Jury FundsEli Lilly (NYS - benzinga.com
Eli Lilly stock gains 2.86 percent as guidance rises - AD HOC NEWS
Editorial: Lilly CEO calls on city, state to get serious about quality of life - Indianapolis Business Journal
Nektar Therapeutics awarded $90 million in jury verdict against Eli Lilly - Investing.com Canada
Viking Therapeutics Soared After Its Latest GLP-1 Data. Is It Too Late to Buy? - The Motley Fool
FDA approves Lilly’s Onswik for type 2 diabetes in adults - Yahoo
91-year-old investor sees healthcare titan doubling in 3 years - thestreet.com
Eli Lilly and Co. stock gains 3.51 percent ahead of the open - AD HOC NEWS
Jurisdictional Skepticism Puts Eli Lilly Appeal On Thin Ice - Law360
RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
Eli Lilly Hit With $90M Verdict In Nektar's Rezpeg Breach Suit - Law360
Eli Lilly (LLY) Stock Is Up, What You Need To Know - Yahoo Finance Australia
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? - The Motley Fool
Eli Lilly & Co. stock outperforms competitors on strong trading day - MarketWatch
Medicare just handed Eli Lilly a massive weight-loss win - sg.finance.yahoo.com
Lilly Again Looks to China for New Drugs, Paying InnoCare $100M to Start R&D Pact - medcitynews.com
FDA approves Eli Lilly's once-weekly insulin On... - Pluang
Eli Lilly and InnoCare sign drug discovery deal worth up to $3.35B - qz.com
Eli Lilly and Company (NYSE:LLY) Anchors Healthcare Focus on Deals and Clearances - Kalkine Media
Lilly Wins FDA Nod For Weekly Insulin, Signs $3.25 Billion InnoCare Pact - benzinga.com
Lilly’s Ricks says state needs to emphasize quality of life, health care - dailyjournal.net
Lilly extends China innovation push in $3.35B Innocare deal - BioWorld News
FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes - Dealroom
InnoCare and Lilly ink deal worth up to $3.35 billion across five drug targets - The Pharma Letter
US FDA approves Lilly's once-weekly insulin injection for type 2 diabetes - Reuters
Eli Lilly Rises After FDA Approval for Once-Weekly Diabetes Insulin - Quiver Quantitative
How Is Lilly (NYSE:LLY) Broadening Its S&P 500 Pipeline Today? - Kalkine Media
Healthcare is a great defensive sector to be in when the rest of the market is crapping in their pants! - Moomoo
Eli Lilly and Co Stock (LLY) Moved Up by 3.73% on Sep 24: A Full Analysis - TradingKey
InnoCare Enters $3.35 Billion Research Collaboration and License Agreement with Eli Lilly - Pharmaceutical Executive
Eli Lilly Stock Price Today (LLY) | NYSE - TechGraph
Governor Abbott Delivers Remarks At Lilly Groundbreaking In Houston - Texas Border Business
Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare - Pharmaceutical Technology
LLY Looks 26.0% Undervalued on GF Value™ After FDA Approval of O - GuruFocus
Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal - pmlive.com
LLY Looks 26.0% Undervalued on GF Value™ After FDA Approval of W - GuruFocus
Eli Lilly signs deal worth up to USD 3.35bn with China's InnoCare - medwatch.com
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes - Eli Lilly
Lilly's FDA-approved weekly insulin could mean over 300 fewer shots a year than daily insulin - Stock Titan
InnoCare and Eli Lilly strike research collaboration worth up to $3.35B - app.dealroom.co
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.20%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):